Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension

Journal of Diabetes and its Complications

Volumn 22, Issue 5, 2008, Pages 303-308

  Jawa, Ali ^a   Nachimuthu, Senthil ^b   Pendergrass, Merri ^c   Asnani, Sunil ^d   Fonseca, Vivian ^d  

^a KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^b Huey P Long Medical Center   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

African American; Beta blockers; Endothelial function; Microalbuminuria; Type 2 diabetes mellitus

Indexed keywords

ALBUMIN; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; METOPROLOL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOPPLER FLOWMETRY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; ECHOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AFRICAN AMERICANS; AGED; ALBUMINS; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CARBAZOLES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; MALE; METOPROLOL; MIDDLE AGED; PROPANOLAMINES;

EID: 50049107001     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.05.003     Document Type: Article

References (27)

1. Bakris G.L., Fonseca V., Katholi R.E., et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. Journal of the American Medical Association 292 18 (2004) 2227-2236
2. Bakris G.L., Mangrum A., Copley J.B., Vicknair N., and Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 29 3 (1997) 744-750
3. Bloche M.G. Race-based therapeutics. New England journal of Medicine 351 20 (2004) 2035-2037
4. Ferdinand K.C. Treating the African American with hypertension: does race really matter?. Southern Medical Journal 93 5 (2000) 541-544
5. Flack J.M., and Hamaty M. Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. Journal of Hypertension. Supplement 17 1 (1999) S19-S24
6. Fonseca V., and Jawa A. Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: Common pathways and treatments?. American Journal of Cardiology 96 12B (2005) 13M-18M
7. Ghiadoni L., Magagna A., Versari D., et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 41 6 (2003) 1281-1286
8. Giugliano D., Acampora R., Marfella R., et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Annals of Internal Medicine 126 12 (1997) 955-959
9. Goldschmid M.G., Domin W.S., Ziemer D.C., Gallina D.L., and Phillips L.S. Diabetes in urban African-Americans: II. High prevalence of microalbuminuria and nephropathy in African-Americans with diabetes. Diabetes Care 18 7 (1995) 955-961
10. Guasch A., Parham M., Zayas C.F., Campbell O., Nzerue C., and Macon E. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with non-insulin-dependent diabetes mellitus and nephropathy. Journal of the American Society of Nephrology 8 5 (1997) 793-798
11. Jawa A., Nachimuthu S., Pendergrass M., Asnani S., and Fonseca V. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin converting enzyme inhibitor therapy. Journal of Clinical Endocrinology and Metabolism 91 1 (2006) 31-35
12. Jones D.S., Andrawis N.S., and Abernethy D.R. Impaired endothelial-dependent forearm vascular relaxation in black Americans. Clinical Pharmacology and Therapeutics 65 4 (1999) 408-412
13. Krum H., Gu A., Wilshire-Clement M., et al. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. American Heart Journal 131 2 (1996) 337-341
14. O'Driscoll G., Green D., Maiorana A., Stanton K., Colreavy F., and Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Journal of the American College of Cardiology 33 6 (1999) 1506-1511
15. Parving H.H. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. Journal of Hypertension. Supplement 8 7 (1990) S187-S191
16. Pavlik V.N., Hyman D.J., Vallbona C., Toronjo C., and Louis K. Hypertension awareness and control in an inner-city African-American sample. Journal of Human Hypertension 11 5 (1997) 277-283
17. Peterson J.C., Adler S., Burkart J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Annals of Internal Medicine 123 10 (1995) 754-762
18. Powers D.R., and Wallin J.D. End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Archives of Internal Medicine 158 7 (1998) 793-800
19. Prisant L.M., and Mensah G.A. Use of beta-adrenergic receptor blockers in blacks. Journal of Clinical Pharmacology 36 10 (1996) 867-873
20. Rahman M., Pressel S., Davis B.R., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 165 8 (2005) 936-946
21. Sica D.A. The African American Study of Kidney Disease and Hypertension (AASK) trial: What more have we learned?. Journal of Clinical Hypertension (Greenwich, Conn.) 5 2 (2003) 159-167
22. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. New England Journal of Medicine 351 20 (2004) 2049-2057
23. Thaler L.M., El Kebbi I.M., Ziemer D.C., Gallina D.L., Dunbar V.G., and Phillips L.S. High prevalence of albuminuria among African-Americans with short duration of diabetes. Diabetes Care 21 9 (1998) 1576-1577
24. Toto R.D., Mitchell H.C., Smith R.D., Lee H.C., McIntire D., and Pettinger W.A. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Iinternational 48 3 (1995) 851-859
25. Winkleby M.A., Kraemer H.C., Ahn D.K., and Varady A.N. Ethnic and socioeconomic differences in cardiovascular disease risk factors: Findings for women from the Third National Health and Nutrition Examination Survey, 1988-1994. Journal of the American Medical Association 280 4 (1998) 356-362
26. Winkleby M.A., Robinson T.N., Sundquist J., and Kraemer H.C. Ethnic variation in cardiovascular disease risk factors among children and young adults: Findings from the Third National Health and Nutrition Examination Survey, 1988-1994. Journal of the American Medical Association 281 11 (1999) 1006-1013
27. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. Journal of the American Medical Association 288 19 (2002) 2421-2431